Relief Therapeutics and Eton Pharmaceuticals Join Forces to Commercialize Golike Products for Phenylketonuria
Shots:
- Relief Therapeutics and Eton Pharmaceuticals have entered into an exclusive license and supply agreement to commercialize products from the Golike portfolio across the US
- Under the collaboration, Relief is entitled to receive $2.2M up front, $2.0M as sales milestones & net-sales-based mid-teens royalties along with rights to Golike outside the US while Eton gains the US rights to Golike Medical Food line extensions for tyrosinemia & homocystinuria anticipated to launch in 2025 & 2026, respectively
- Relief and Eton are also under discussion regarding other assets, incl. RLF-OD032, for the treatment of PKU. It's 505(b)(2) application with the US FDA is anticipated in H2’25
Ref: Relief Therapeutics | Image: Relief Therapeutics
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Tags
Disha is a content writer at PharmaShots. She is passionate and curious about recent updates and developments in MedTech and Pharma industry. She covers news related to clinical trial results and updates. She can be contacted at connect@pharmashots.com.
